The majority of analysts have given bullish ratings to Viridian Therapeutics, with recent price targets showing an upward trend. This indicates a positive sentiment among analysts, despite the company's financial challenges such as declining revenue and negative margins. The increase in price targets suggests that analysts expect potential growth, which could positively impact the stock price in the short term.